Standout Papers

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy 2021 2026 2022 2024160
  1. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy (2021)
    Jerry R. Mendell, Samiah Al-Zaidy et al. JAMA Neurology

Citation Impact

2 from Science/Nature 70 standout
Sub-graph 1 of 21

Citing Papers

Past, present, and future of CRISPR genome editing technologies
2024 Standout
Rapid in silico directed evolution by a protein language model with EVOLVEpro
2024 StandoutScience
1 intermediate paper

Works of Markus McColly being referenced

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
2021 Standout

Author Peers

Author Genetics Molecular Biology Surgery Last Decade Papers Cites
Markus McColly 236 262 158 11 391
Dorothy Abel 113 15 352
Tália Santana Machado de Assis 3 11 2 29 423
Fabien Cousin 798 17 21 1.2k
Claire A. Klepner 604 2 11 1.4k
Isabel Piel 10 84 1 16 1.3k

All Works

Loading papers...

Rankless by CCL
2026